Market News

Juniper Pharmaceuticals, Inc. (JNP) Analysts See $0.02 EPS; DexCom, Inc. (DXCM) Covered By 17 Bullish Analysts Last Week

DexCom, Inc. (NASDAQ:DXCM) Logo

Among 25 analysts covering Dexcom (NASDAQ:DXCM), 17 have Buy rating, 2 Sell and 6 Hold. Therefore 68% are positive. Dexcom had 73 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Overweight” rating by JP Morgan on Thursday, September 17. The company was maintained on Wednesday, November 2 by Canaccord Genuity. The firm has “Outperformer” rating given on Wednesday, August 2 by BMO Capital Markets. Benchmark maintained it with “Buy” rating and $86 target in Wednesday, February 24 report. The stock has “Buy” rating by Canaccord Genuity on Thursday, September 28. The rating was maintained by Canaccord Genuity with “Buy” on Monday, September 25. Jefferies maintained DexCom, Inc. (NASDAQ:DXCM) rating on Thursday, December 21. Jefferies has “Buy” rating and $70.0 target. As per Wednesday, February 28, the company rating was maintained by Canaccord Genuity. The rating was downgraded by BTIG Research on Wednesday, September 14 to “Neutral”. As per Thursday, July 13, the company rating was maintained by Jefferies. See DexCom, Inc. (NASDAQ:DXCM) latest ratings:

11/04/2018 Broker: Cowen & Co Rating: Buy New Target: $85.0000 Maintain
09/04/2018 Broker: Stephens Rating: Buy New Target: $78.0000 Maintain
04/04/2018 Broker: Guggenheim Rating: Neutral Initiates Coverage On
04/04/2018 Broker: Goldman Sachs Rating: Sell New Target: $57 Initiates Coverage On
28/03/2018 Broker: BMO Capital Markets Rating: Buy New Target: $78.0000 Maintain
28/03/2018 Broker: Cowen & Co Rating: Buy New Target: $75.0000 Maintain
28/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $71.0000 Maintain
23/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $78.0000 Maintain
23/03/2018 Broker: Robert W. Baird Old Rating: Neutral New Rating: Outperform Old Target: $58 Upgrade
28/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $62 New Target: $71 Maintain

Analysts expect Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) to report $0.02 EPS on May, 3.They anticipate $0.15 EPS change or 115.38% from last quarter’s $-0.13 EPS. JNP’s profit would be $219,505 giving it 118.13 P/E if the $0.02 EPS is correct. After having $0.11 EPS previously, Juniper Pharmaceuticals, Inc.’s analysts see -81.82% EPS growth. The stock decreased 1.05% or $0.1 during the last trading session, reaching $9.45. About 30,336 shares traded. Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has risen 88.04% since April 16, 2017 and is uptrending. It has outperformed by 76.49% the S&P500.

Juniper Pharmaceuticals, Inc., a women's health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company has market cap of $103.72 million. The firm develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring technology. It currently has negative earnings. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency.

Among 5 analysts covering Juniper Pharmaceuticals Inc (NASDAQ:JNP), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Juniper Pharmaceuticals Inc had 7 analyst reports since August 26, 2015 according to SRatingsIntel. The rating was upgraded by TheStreet on Wednesday, August 26 to “Buy”. The stock of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) earned “Market Perform” rating by Northland Capital on Thursday, August 18. The firm has “Buy” rating given on Tuesday, January 2 by Roth Capital. The firm has “Outperform” rating by Northland Capital given on Tuesday, January 26. The firm earned “Market Perform” rating on Monday, January 9 by Bernstein. The rating was downgraded by H.C. Wainwright on Friday, August 19 to “Neutral”.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $6.36 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

Investors sentiment decreased to 0.73 in Q4 2017. Its down 0.24, from 0.97 in 2017Q3. It is negative, as 44 investors sold DexCom, Inc. shares while 97 reduced holdings. 48 funds opened positions while 55 raised stakes. 99.11 million shares or 0.83% more from 98.30 million shares in 2017Q3 were reported. Atlantic Trust Grp Inc Limited Liability Corporation reported 1,000 shares. Envestnet Asset Management invested 0% in DexCom, Inc. (NASDAQ:DXCM). Oppenheimer Asset Management reported 5,409 shares. 7,113 are owned by Highland Mgmt Limited Liability. Schwab Charles Investment Management Inc holds 262,764 shares. Gabelli Funds Lc accumulated 0.02% or 64,000 shares. Carroll Finance Associates Incorporated invested in 0% or 156 shares. Joel Isaacson & Limited Liability Company holds 0.04% or 4,500 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 4,546 shares. Deutsche Bancshares Ag has invested 0% in DexCom, Inc. (NASDAQ:DXCM). Bb&T Secs Limited Liability owns 5,063 shares or 0% of their US portfolio. Manufacturers Life Insurance The owns 2,983 shares for 0% of their portfolio. Bkd Wealth Advsrs Limited Com, a Missouri-based fund reported 4,154 shares. Fdx reported 23,071 shares. Bokf Na holds 6,441 shares or 0.01% of its portfolio.

The stock increased 1.06% or $0.77 during the last trading session, reaching $73.15. About 114,205 shares traded. DexCom, Inc. (NASDAQ:DXCM) has declined 16.08% since April 16, 2017 and is downtrending. It has underperformed by 27.63% the S&P500.

Since October 23, 2017, it had 0 insider purchases, and 9 insider sales for $2.77 million activity. 10,000 DexCom, Inc. (NASDAQ:DXCM) shares with value of $655,122 were sold by GREGG TERRANCE H. DOUBLEDAY RICHARD had sold 1,635 shares worth $73,274. 3,245 shares valued at $198,691 were sold by Balo Andrew K on Monday, December 11. Shares for $353,092 were sold by SAYER KEVIN R on Tuesday, December 12.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *